Showing 1351-1360 of 5771 results for "".
- Ocular Therapeutix Announces Accelerated Timelines for SOL-1 Registrational Trial of Axpaxli in Wet AMDhttps://modernod.com/news/ocular-therapeutix-announces-accelerated-timelines-for-sol-1-registrational-trial-of-axpaxli-in-wet-amd/2482490/Ocular Therapeutix announced an acceleration of the SOL-1 phase 3 registrational clinical trial of Axpaxli for wet age-related macular degeneration (wet AMD). The company now expects to complete enrollment and randomization by the end of 2024, ahead of previous guidance to finish by the first qua
- Alcon to Showcase Latest Innovations at AAO 2024 Annual Meetinghttps://modernod.com/news/alcon-to-showcase-latest-innovations-at-aao-2024-annual-meeting/2482489/Alcon will unveil its latest clinical data and product innovations at the American Academy of Ophthalmology (AAO) 2024 annual meeting. Attendees, including ophthalmologists, surgical staff, researchers, and industry leaders, are invited to visit Alcon at booth #4008 for hands-on demonstrations an
- Glaukos to Showcase Technologies at 2024 AAO Annual Meeting in Chicagohttps://modernod.com/news/glaukos-to-showcase-technologies-at-2024-aao-annual-meeting-in-chicago/2482483/Glaukos announced that its technologies will be featured in various scientific programming at the American Academy of Ophthalmology (AAO) annual meeting, October 18-21, 2024, in Chicago. Glaukos is also sponsoring an educational symposium in conjunction with EyeWorld and AAO entitl
- Melt Announces Completion of Patient Dosing in Phase 3 Study of MELT-300 for Procedural Sedationhttps://modernod.com/news/melt-pharmaceuticals-announces-completion-of-patient-dosing-in-phase-3-study-of-melt-300-for-procedural-sedation/2482477/Melt Pharmaceuticals announced the completion of patient dosing in its pivotal phase 3 clinical trial. This study evaluates the safety and efficacy of MELT-300, the company's lead product candidate, for providing non-intravenous, non-opioid sedation during cataract surgery. MELT-300
- Rayner Announces First RayOne Galaxy Implantations in the UShttps://modernod.com/news/rayner-announces-first-rayone-galaxy-implantations-in-the-us/2482467/Rayner has announced the implantation of the first IOL in the RayOne Galaxy FDA-approved investigational device exemption (IDE) study. This milestone marks the beginning of a prospective, multicenter, randomized, masked, and active-controlled study aimed at evaluating the RayOne Galaxy
- Novaliq and Laboratoires Théa Announce EU Approval for Vevizye for Dry Eye Diseasehttps://modernod.com/news/novaliq-and-laboratoires-thea-announce-partnership-and-eu-approval-for-vevizye/2482466/Novaliq and Laboratoires Théa announced the European Commission’s approval of Vevizye (ciclosporin 0.1% eye drops solution) for the treatment of moderate to severe dry eye disease (DED) in adults unresponsive to tear substitutes. Vevizye is based on Nova
- Oculis and Euretina Announce Winner of Inaugural Ramin Tadayoni Awardhttps://modernod.com/news/oculis-and-euretina-announce-winner-of-inaugural-ramin-tadayoni-award/2482449/Oculis, in partnership with Euretina, has announced the first recipient of the Ramin Tadayoni Award: Dr. Andrea Govetto, MD, PhD. The award honors the memory of Oculis' late Chief Scientific Officer and renowned retina specialist, Professor Ramin Tadayoni, MD, who passed away unexpectedly ear
- Microsurgical Technology (MST) Announces Global Partnership with Vista Ophthalmicshttps://modernod.com/news/microsurgical-technology-mst-announces-global-partnership-with-vista-ophthalmics/2482446/Microsurgical Technology (MST) announced an exclusive global partnership with ophthalmic device company Vista Ophthalmics that will introduce Vista Ophthalmics' products—Vista 1-Step and Vista IS—to the global market. Financial terms of the deal were not disclosed.
- Alkeus Pharmaceuticals Announces Positive Results from SAGA Study of Gildeuretinol Acetate in GA Patientshttps://modernod.com/news/alkeus-pharmaceuticals-announces-positive-results-from-saga-study-of-gildeuretinol-acetate-in-ga-patients-3/2482445/Alkeus Pharmaceuticals announced results from the SAGA study, a phase 3 clinical trial of oral gildeuretinol acetate (ALK-001) in patients with geographic atrophy (GA) secondary to age-related macular degeneration (AMD). The study demonstrated a reduction in the growth rate of GA lesions by
- Viridian Announces Positive Topline Results from Phase 3 Trial of Veligrotug for TEDhttps://modernod.com/news/viridian-announces-positive-topline-results-from-phase-3-trial-of-veligrotug-for-thyroid-eye-disease/2482434/Viridian Therapeutics announced positive topline data from its THRIVE phase 3 clinical trial of VRDN-001, now branded as veligrotug, in patients with active thyroid eye disease (TED). Veligrotug, an intravenously administered anti-insulin-like growth factor-1 receptor (IGF-1R) antibody, demo